RxDoctor Payments Data

Loren Smith, MD

Urology · Topeka, KSNPI 1194792572

Payments from drug & device makers

What this record shows

This record is dominated by education: $3,012 of the $4,066 with a category attached, or 74.1%. Intuitive Surgical accounts for 73.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2020 at $3,144 and has fallen 96.7% since, to $102 in 2025.

$4,066in general payments, 2019–2025

Across 65 payments — averaging $62.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Astellas Pharma US Inc$209
  • 180 Medical, Inc.$204
  • AbbVie$137
  • Convatec Inc.$78
  • Pfizer$70
  • plus $370 from 14 others

What the payments were for

  • Food & beverage$1,05526%
  • Education$3,01274%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,066 in reported general payments places this provider in the 65th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$258,660
Medicare patients
846
Services billed
4,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron112$73,316
Tolterodine Tartrate ErTolterodine Tartrate203$22,322
GemtesaVibegron32$18,319
Tamsulosin Hcl689$9,082
Oxybutynin Chloride ErOxybutynin Chloride218$7,738
Fesoterodine Fumarate ErFesoterodine Fumarate71$7,569
Trospium Chloride ErTrospium Chloride33$5,767
Methenamine Hippurate46$4,327
Solifenacin Succinate106$4,186
Silodosin37$3,166
Estradiol40$3,070
Trospium Chloride40$2,983
Finasteride177$2,949
Potassium Citrate ErPotassium Citrate38$1,789
YuvafemEstradiol15$1,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$209$73,316112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 111 urology providers in Kansas.

Other urology in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →